Genmab presents subgroup data affirming epcoritamab combination success across lymphoma risk brackets
Genmab (NASDAQ:GMAB) announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, which evaluates the subcutaneous T-cell engaging bispecific antibody epcoritamab in combination with rituximab and lenalidomide (epcoritamab plus R2).










-640x360.webp&w=3840&q=75)